Skip to main content
Hit enter to search or ESC to close
Close Search
MedincellMedincellMedincell
search
Menu
  • About Us
    • Impact companyPurposeful innovation coupled with a responsible company model can positively impact Global Health
    • Our peopleOur strength: valuing and nurturing our team’s entrepreneurial spirit, expertise, and dedication
    • Leadership TeamSeasoned leaders unite to tackle global health challenges
  • Science
    • UZEDY®Relapse prevention long-acting treatment for schizophrenia
    • R&D PipelineAdvancing therapeutic care with precision Delivery
    • BEPO® technologyOur technology platform to develop long-acting treatments
    • PublicationsFacilitate collaboration with our collection of scientific articles and presentations
  • Responsibility
    • Our commitmentsTransforming global health with purposeful innovation
    • Code and policiesHigh standards for all company’s stakeholders
    • 2025 ESG reportSocial and environmental information about the company and its activities
  • Careers
    • Our vision & our valuesSee how our HR vision and values shape a dynamic workforce
    • Work environment & benefitsExplore the benefits and environment driving our team’s success
    • Join usEmbark on a career journey where your talents meet opportunity
  • News & events
    • NewsroomLatest updates and announcements, the gateway to all press releases
    • EventsEarnings calls, conferences, General Meeting: live and replay
  • Investors
    • OverviewAll information and news about Medincell stock
    • Reports & regulated informationFinancial reports, operational updates, and shareholder information
    • General MeetingAll documents related to the Medincell Shareholders’ Meetings
    • Leadership teamSeasoned leaders unite to tackle global health challenges
  • Contact
  • EN
  • FR
  • search
Category

Investors

MedinCell announces the availability of its 2019/2020 Universal Registration Document including the Annual Financial Report

July 29, 2020
July 29, 2020

MedinCell announces the great success of its capital increase and raises 15.6 M€

June 16, 2020
June 16, 2020

MedinCell launches a capital increase of a minimum of 11 M€

June 15, 2020
June 15, 2020

MedinCell successfully renegotiates the drawdown conditions of the last tranche of the EIB loan and secures an additional €5m of non-dilutive funding

June 10, 2020
June 10, 2020

Video Conference • Annual results

June 4, 2020

MedinCell announces fiscal year consolidated results April 2019 – March 2020

June 4, 2020
June 4, 2020

Videoconference and publication of the results for the 2019-2020 financial year, on June 4, 2020

May 25, 2020
May 25, 2020

Videoconference • Adapt and overcome to the Covid-19 crisis

April 23, 2020

Adapt and overcome in response to the Covid-19 crisis

April 23, 2020
April 23, 2020

MedinCell launches Regulatory Development of mdc-WWM Program

April 22, 2020
April 22, 2020
  • Previous
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 22
  • Next

Articles récents

  • [Replay] Webcast – HY Results – Dec. 9, 2025
  • Half Year Results 2025-26 (12.09.2025)
  • Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)
  • Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
  • Videoconference and publication of half-year financial results, Tuesday, December 9, 2025

Commentaires récents

No comments to show.

Stay tuned, leave your email

About us

Science

Responsibility

Investors

Careers

News & events

Contact

Ethics line

Legal notices

Privacy policy

Better medicine for all

© 2024 Medincell. All rights reserved.

Website by ScreenUp

Close Menu
  • Home
  • About Us
    • Impact company
    • Our people
    • Leadership team
  • Science
    • UZEDY®
    • R&D Pipeline
    • BEPO® technology
    • Publications
  • Responsibility
    • Our commitments
    • Code and policies
    • 2025 ESG Report
  • Careers
    • Our vision & our values
    • Work environment & benefits
    • Join us
  • News & events
    • News
    • Events
  • Investors
    • Overview
    • Regulated information
    • General Meeting
    • Leadership team
  • Contact
  • FR